Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke

Vadim Karepov, Galina Tolpina, Wiktor Kuliczkowski, Victor Serebruany

Research output: Contribution to journalArticle

Abstract

Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as 'resistance', is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3-26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60% were women, and over 85% of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such 'strong' protected platelets.

Original languageEnglish (US)
Pages (from-to)272-276
Number of pages5
JournalCerebrovascular Diseases
Volume26
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Aspirin
Triglycerides
Blood Platelets
Stroke
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Membrane Fluidity
Hypertriglyceridemia
Prostaglandin-Endoperoxide Synthases
Secondary Prevention
HDL Cholesterol
Survivors
Polymers
Down-Regulation
Biomarkers
Demography
Technology

Keywords

  • Aspirin
  • Platelets
  • Stroke
  • Triglycerides

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. / Karepov, Vadim; Tolpina, Galina; Kuliczkowski, Wiktor; Serebruany, Victor.

In: Cerebrovascular Diseases, Vol. 26, No. 3, 09.2008, p. 272-276.

Research output: Contribution to journalArticle

Karepov, Vadim ; Tolpina, Galina ; Kuliczkowski, Wiktor ; Serebruany, Victor. / Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. In: Cerebrovascular Diseases. 2008 ; Vol. 26, No. 3. pp. 272-276.
@article{f4f0100c54e54494a2299186c8267fff,
title = "Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke",
abstract = "Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25{\%}. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as 'resistance', is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3-26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60{\%} were women, and over 85{\%} of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such 'strong' protected platelets.",
keywords = "Aspirin, Platelets, Stroke, Triglycerides",
author = "Vadim Karepov and Galina Tolpina and Wiktor Kuliczkowski and Victor Serebruany",
year = "2008",
month = "9",
doi = "10.1159/000147455",
language = "English (US)",
volume = "26",
pages = "272--276",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke

AU - Karepov, Vadim

AU - Tolpina, Galina

AU - Kuliczkowski, Wiktor

AU - Serebruany, Victor

PY - 2008/9

Y1 - 2008/9

N2 - Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as 'resistance', is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3-26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60% were women, and over 85% of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such 'strong' protected platelets.

AB - Background: Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%. Platelet function monitoring in ASA users suggests that some individuals exhibit a reduced or even absent antiplatelet response after ASA. This phenomenon, also known as 'resistance', is prevalent in stroke survivors. We sought to evaluate the blood lipid profile in poststroke ASA users dependent on their antiplatelet response to ASA. Methods: Ninety-six consecutive ASA users after first-ever ischemic stroke confirmed by imaging were prospectively enrolled. The platelet function analyzer (PFA-100, Dade Behring, USA) was utilized to assess the response after ASA. The lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides) was measured using the Cardiochek instrument (Polymer Technology, USA) from the autologuos blood samples. Results: The poststroke duration was 3-26 months, and all patients were treated with ASA for at least 3 months. The allowed daily ASA doses were from 75 up to 325 mg, with a mean of 158 mg. The mean age of the patients was 71 years, almost 60% were women, and over 85% of the patients were treated with statins. Thirty-seven patients were identified as low ASA responders, while 59 patients exhibited an adequate response. There were no differences between ASA responders and nonresponders with regard to demographics, clinical characteristics, risk factors and concomitant medications. The lipid profile biomarkers were similar between groups with the exception of triglycerides, which were significantly increased in the patients with ASA resistance, compared with ASA responders. Conclusion: The fact that hypertriglyceridemia affects platelet response to ASA has potential practical implications in light of growing evidence that ASA may exert antiplatelet properties beyond the cyclooxygenase pathway. The mechanism of such an association is unclear but may be related to the diminished platelet membrane fluidity and inability of ASA to downregulate such 'strong' protected platelets.

KW - Aspirin

KW - Platelets

KW - Stroke

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=47549102119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549102119&partnerID=8YFLogxK

U2 - 10.1159/000147455

DO - 10.1159/000147455

M3 - Article

C2 - 18648200

AN - SCOPUS:47549102119

VL - 26

SP - 272

EP - 276

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 3

ER -